moclobemide has been researched along with Parkinson Disease in 6 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Distinto, S | 1 |
| Yáñez, M | 1 |
| Alcaro, S | 1 |
| Cardia, MC | 1 |
| Gaspari, M | 1 |
| Sanna, ML | 1 |
| Meleddu, R | 1 |
| Ortuso, F | 1 |
| Kirchmair, J | 1 |
| Markt, P | 1 |
| Bolasco, A | 1 |
| Wolber, G | 1 |
| Secci, D | 1 |
| Maccioni, E | 1 |
| Sieradzan, K | 1 |
| Channon, S | 1 |
| Ramponi, C | 1 |
| Stern, GM | 1 |
| Lees, AJ | 1 |
| Youdim, MB | 1 |
| Illi, A | 1 |
| Sundberg, S | 1 |
| Ojala-Karlsson, P | 1 |
| Scheinin, M | 1 |
| Gordin, A | 1 |
| Ruggieri, S | 1 |
| Fabbrini, G | 1 |
| Bramante, L | 1 |
| DePandis, F | 1 |
| Stocchi, F | 1 |
| Barbanti, P | 1 |
| Vacca, L | 1 |
| Manfredi, M | 1 |
| Steur, EN | 1 |
| Ballering, LA | 2 |
| Jansen Steur, EN | 1 |
5 trials available for moclobemide and Parkinson Disease
| Article | Year |
|---|---|
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Topics: Adult; Affect; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Benzamides; Cognition; Dr | 1995 |
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Topics: Administration, Oral; Adult; Analysis of Variance; Antidepressive Agents; Antiparkinson Agents; Benz | 1996 |
An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
Topics: Antiparkinson Agents; Benzamides; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Mi | 1996 |
Moclobemide and selegeline in the treatment of depression in Parkinson's disease.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1997 |
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Topics: Adult; Aged; Benzamides; Cognition; Depression; Drug Combinations; Female; Humans; Male; Medical Rec | 1999 |
1 other study available for moclobemide and Parkinson Disease
| Article | Year |
|---|---|
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dyn | 2012 |